NASDAQ:RARX - Ra Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$23.34 -0.86 (-3.55 %)
(As of 03/26/2019 04:00 PM ET)
Previous Close$24.20
Today's Range$22.96 - $24.43
52-Week Range$4.78 - $27.68
Volume302,311 shs
Average Volume464,265 shs
Market Capitalization$984.67 million
P/E Ratio-11.33
Dividend YieldN/A
Beta0.83
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Receive RARX News and Ratings via Email

Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARX
CUSIPN/A
Phone617-401-4060

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.50 million
Book Value$4.92 per share

Profitability

Net Income$-64,940,000.00

Miscellaneous

Employees72
Market Cap$984.67 million
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable

Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions

What is Ra Pharmaceuticals' stock symbol?

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals Inc (NASDAQ:RARX) released its quarterly earnings data on Thursday, March, 7th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. The firm earned $2.50 million during the quarter, compared to analysts' expectations of $2.50 million. View Ra Pharmaceuticals' Earnings History.

When is Ra Pharmaceuticals' next earnings date?

Ra Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Ra Pharmaceuticals.

What price target have analysts set for RARX?

7 analysts have issued 12 month price objectives for Ra Pharmaceuticals' shares. Their forecasts range from $25.00 to $55.00. On average, they expect Ra Pharmaceuticals' share price to reach $40.00 in the next twelve months. This suggests a possible upside of 71.4% from the stock's current price. View Analyst Price Targets for Ra Pharmaceuticals.

What is the consensus analysts' recommendation for Ra Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ra Pharmaceuticals.

Has Ra Pharmaceuticals been receiving favorable news coverage?

News headlines about RARX stock have been trending very negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ra Pharmaceuticals earned a coverage optimism score of -3.6 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future.

Who are some of Ra Pharmaceuticals' key competitors?

What other stocks do shareholders of Ra Pharmaceuticals own?

Who are Ra Pharmaceuticals' key executives?

Ra Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas A. Treco, Co-Founder, Pres, CEO & Director (Age 61)
  • Mr. David C. Lubner, Exec. VP & CFO (Age 55)
  • Dr. Ramin Farzaneh-Far, Chief Medical Officer (Age 42)
  • Dr. Simon Read, Chief Scientific Officer (Age 48)
  • Mr. Alonso Ricardo, Sr. VP of R&D

When did Ra Pharmaceuticals IPO?

(RARX) raised $75 million in an initial public offering (IPO) on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Who are Ra Pharmaceuticals' major shareholders?

Ra Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (18.95%), RA Capital Management LLC (15.00%), BlackRock Inc. (8.16%), First Manhattan Co. (4.49%), Candriam Luxembourg S.C.A. (2.71%) and Sectoral Asset Management Inc (2.47%). Company insiders that own Ra Pharmaceuticals stock include Bioventures Ltd Novartis, Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Institutional Ownership Trends for Ra Pharmaceuticals.

Which institutional investors are selling Ra Pharmaceuticals stock?

RARX stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Algert Global LLC, Squarepoint Ops LLC and Barclays PLC. View Insider Buying and Selling for Ra Pharmaceuticals.

Which institutional investors are buying Ra Pharmaceuticals stock?

RARX stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management LLC, NEA Management Company LLC, BlackRock Inc., Sectoral Asset Management Inc, Candriam Luxembourg S.C.A., First Manhattan Co., FMR LLC and Millennium Management LLC. Company insiders that have bought Ra Pharmaceuticals stock in the last two years include Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Ra Pharmaceuticals.

How do I buy shares of Ra Pharmaceuticals?

Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ra Pharmaceuticals' stock price today?

One share of RARX stock can currently be purchased for approximately $23.34.

How big of a company is Ra Pharmaceuticals?

Ra Pharmaceuticals has a market capitalization of $984.67 million and generates $2.50 million in revenue each year. The company earns $-64,940,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Ra Pharmaceuticals employs 72 workers across the globe.

What is Ra Pharmaceuticals' official website?

The official website for Ra Pharmaceuticals is http://www.rapharma.com.

How can I contact Ra Pharmaceuticals?

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]


MarketBeat Community Rating for Ra Pharmaceuticals (NASDAQ RARX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  172 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote "Outperform" if you believe RARX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel